In prostate cancer, the upregulation of ST6GAL1 promotes the growth and metastatic spread of prostate tumours to bone [52,77], and targeting aberrant sialylation in prostate cancer cells can inhibit the metastatic spread of tumours to bone [51,52]. This evidence concerns the gene ST6GAL1 and prostate neoplasm.